Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: chloride ion channel antagonists - Nordic Bioscience

Drug Profile

Research programme: chloride ion channel antagonists - Nordic Bioscience

Alternative Names: NS 3736

Latest Information Update: 02 Dec 2013

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator NeuroSearch; Nordic Bioscience
  • Developer Nordic Bioscience
  • Class
  • Mechanism of Action Chloride channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Postmenopausal osteoporosis

Most Recent Events

  • 15 Sep 2009 Preclinical trials in Postmenopausal osteoporosis in Denmark (unspecified route)
  • 13 Jul 2006 Discontinued - Preclinical for Postmenopausal osteoporosis in Denmark (unspecified route)
  • 16 Jun 2004 Data presented at the World Congress on Osteoporosis (WCO-2004) have been added to the Musculoskeletal disorders pharmacodynamics section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top